Current Report Filing (8-k)
28 January 2023 - 05:26AM
Edgar (US Regulatory)
0001788028
false
0001788028
2023-01-27
2023-01-27
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2023-01-27
2023-01-27
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2023-01-27
2023-01-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report
(Date of earliest event reported): January 27, 2023
JASPER THERAPEUTICS,
INC.
(Exact Name
of Registrant as Specified in its Charter)
Delaware |
|
001-39138 |
|
84-2984849 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
2200 Bridge
Pkwy Suite #102
Redwood City,
California 94065
(Address of
Principal Executive Offices) (Zip Code)
(650) 549-1400
Registrant’s
telephone number, including area code
N/A
(Former Name,
or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
(Title
of each class) |
|
(Trading
Symbol) |
|
(Name
of exchange on which registered) |
Voting Common Stock, par value $0.0001 per share |
|
JSPR |
|
The
Nasdaq Stock Market LLC |
Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01.
Other Events.
On
January 27, 2023, Jasper Therapeutics, Inc. (the “Company”) issued a press release announcing the closing of its previously
announced underwritten public offering of shares of its voting common stock, $0.0001 par value per share (“Common Stock”).
In the offering, the Company sold an aggregate of 69,000,000 shares of Common Stock at a public offering price of $1.50 per share, which
includes the exercise in full by the underwriters of their option to purchase 9,000,000 additional shares of Common Stock. A copy of
the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01.
Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
JASPER THERAPEUTICS, INC. |
|
|
Date: January 27, 2023 |
By: |
/s/ Jeet Mahal |
|
Name: |
Jeet Mahal |
|
Title: |
Chief Operating Officer and Chief Financial Officer |
2
Amplitude Healthcare Acq... (NASDAQ:AMHC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amplitude Healthcare Acq... (NASDAQ:AMHC)
Historical Stock Chart
From Mar 2023 to Mar 2024